• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Thursday, February 2, 2023
Massachusetts Digital News
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • US
  • Business
  • World
  • Boston
  • Worcester
  • Springfield
  • Cambridge
  • Lowell
  • Brockton
  • Press Releases
  • Videos
No Result
View All Result
No Result
View All Result
Home Cambridge

Leap Therapeutics : To Present Positive New Data From The DisTinGuish Study Of DKN-01 Plus Tislelizumab At The ASCO GI Cancers Symposium – Form 8-K | MarketScreener

by Duong
January 18, 2022
in Cambridge
leap-therapeutics-:-to-present-positive-new-data-from-the-distinguish-study-of-dkn-01-plus-tislelizumab-at-the-asco-gi-cancers-symposium-–-form-8-k-|-marketscreener
Share on FacebookShare on Twitter

01/18/2022 | 05:12pm EST

share with twitter

share with LinkedIn

share with facebook

Leap Therapeutics to Present Positive New Data from the DisTinGuish Study

of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium

–    DKN-01 plus tislelizumab demonstrated encouraging clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients

–    10.7 months PFS in overall first-line population; higher 11.9 months PFS in DKK1-high patients

–    Company to host conference call on Friday, January 21, 2022 at 1:00 p.m. ET

Cambridge, MA – January 18, 2022 – Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap’s anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene’s anti-PD-1 antibody, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium being held on January 20-22, 2022.

The Company will host a conference call with Dr. Samuel Klempner of Harvard Medical School and Massachusetts General Hospital on Friday, January 21, 2022 to discuss results from the study.

The latest results from Part A of the DisTinGuish study will be presented, representing first-line advanced G/GEJ patients treated with DKN-01 in combination with tislelizumab and chemotherapy. New data demonstrate compelling efficacy from this combination regimen, driven by enhanced clinical responses and survival benefit associated with high tumoral DKK1 expression that is independent of PD-L1 expression. Also to be presented are initial findings from the still-enrolling Part B of the clinical trial, studying DKN-01 and tislelizumab in second-line advanced G/GEJ patients with high tumoral DKK1 expression, showing the treatment is well tolerated with encouraging objective responses observed.

“The combination of DKN-01 with tislelizumab continues to demonstrate encouraging results in patients with gastric and gastroesophageal junction cancer, especially those in the DKK1-high subpopulation,” said Samuel Klempner, MD, Associate Professor at Harvard Medical School who leads the gastric and esophageal cancer program at Massachusetts General Hospital Cancer Center and is a principal investigator on the DisTinGuish study. “The updated front-line results are encouraging in a difficult to treat cohort of primarily PD-L1 low patients, who are less likely to benefit from anti-PD-1 therapy. Together with encouraging initial findings from Part B, where DKN-01 and tislelizumab are used as a chemo-free second-line treatment of DKK1 high-expressing tumors, these results continue to support the therapeutic potential of DKN-01 and warrant exploration in a randomized clinical trial in first-line gastric and gastroesophageal junction patients.”

About the DisTinGuish Study

The DisTinGuish study (NCT04363801) is a Phase 2a study of DKN-01 in combination with tislelizumab, an anti-PD-1 antibody, with or without chemotherapy as first-line or second-line therapy in patients with inoperable, locally advanced, G/GEJ adenocarcinoma. The study is being conducted in two parts in the United States and the Republic of Korea. Enrollment of Part A has been completed with 25 first-line HER2- G/GEJ cancer patients whose tumors express either high levels of DKK1 (DKK1-high) or low levels of DKK1 (DKK1-low). Part B of the study has enrolled 30 patients with second-line DKK1-high G/GEJ cancer and will continue to enroll up to 48 patients. Leap is conducting this combination study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia, and New Zealand.

First-Line Part A Key Findings

· Overall preliminary median progression-free survival (PFS) was 10.7 months
o PFS was longer in DKK1-high patients at 11.9 months, compared to 10.7 months in DKK1-low patients
· Preliminary median duration of response (DoR) was 10.7 months in DKK1-high patients, compared to 7.9 months in DKK1-low patients
· Median overall survival has not been reached
· Among patients who received a full first cycle of DKN-01 (modified intent to treat, n=22), the objective response rate (ORR) was 68%, including one complete response (CR) and 14 partial responses (PR)
o 90% ORR in DKK1-high patients (n=10)
o 56% ORR in DKK1-low patients (n=9)
· Activity was independent of PD-L1 expression
o 79% ORR in PD-L1-low (vCPS < 5) and 67% ORR in PD-L1-high (vCPS > 5) patients
o 100% ORR in DKK1-high, PD-L1-low patients (n=6)
· Combination was well tolerated, safety profile consistent with previous update and reflecting the underlying patient population

Second-Line Part B Key Findings

· DKN-01 and tislelizumab administered in DKK1-high, PD-1 naïve patients was well tolerated at both 300mg and 600mg DKN-01 doses
· Among evaluable patients who received a full first cycle of DKN-01 (response evaluable modified intent to treat, n=20), the objective response rate (ORR) was 25%, including 5 PRs and 4 stable disease (SD). One additional patient has had an irPR by iRECIST criteria.
· PD-L1 expression is low overall in the study population and not correlated with DKK1 expression
· The study is ongoing and enrolling in the 600mg DKN-01 cohort. Twelve patients were on study at the time of the data cut, four of whom had not yet had their first imaging assessment.

Leap Presentation Details:

Title: DKN-01 and Tislelizumab ± Chemotherapy as a First-Line (1L) and Second-Line (2L) Investigational Therapy in Advanced Gastroesophageal Adenocarcinoma (GEA): DisTinGuish Trial

Session Type: Poster Session

Presenter: Samuel J. Klempner, Harvard Medical School

Date and Time: Thursday, January 20, 2022 at 3:00 p.m. Eastern Time

Conference Call

Leap will host a conference call on Friday, January 21, 2022 at 1:00 p.m. Eastern Time to further discuss the data. In addition to Leap’s executive management team, Dr. Samuel Klempner of Harvard Medical School and Massachusetts General Hospital will be on the call. The call can be accessed by dialing (866) 589-0108 (U.S. and Canada) or (409) 231-2048 (international). The passcode for the conference call is 3323348. The presentation will be webcast live and may be accessed on the Investors page of the Company’s website at https://investors.leaptx.com/, where a replay of the event will also be available for a limited time.

About DKN-01

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and has an important role in promoting tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The U.S. Food and Drug Administration has granted DKN-01 Orphan Drug Designation for the treatment of gastric and gastroesophageal junction cancer and Fast Track Designation in combination with tislelizumab for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors express high DKK1 protein, following disease progression on or after prior fluoropyrimidine- and platinum- containing chemotherapy and if appropriate, human epidermal receptor growth factor (HER2)/neu-targeted therapy.

About Leap Therapeutics

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, gynecologic, and prostate cancers. Leap has entered into a strategic collaboration with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include Leap’s expectations with respect to the development and advancement of DKN-01, including the initiation, timing and design of clinical studies, enrollment in clinical studies, and other future expectations, plans and prospects. Although Leap believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from our expectations. Such risks and uncertainties include, but are not limited to: that the initiation, conduct, and completion of clinical trials, laboratory operations, manufacturing campaigns, and other studies may be delayed, adversely affected, or impacted by COVID-19 related issues; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; the size and growth potential of the markets for our drug product candidates; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics’ periodic filings with the SEC, including Leap’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC on March 12, 2021 and as may be updated by Leap’s Quarterly Reports on Form 10-Q and the other reports Leap files from time to time with the SEC. Any forward-looking statement contained in this release speaks only as of its date. Leap undertakes no obligation to update any forward-looking statement contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT:

Douglas E. Onsi

President & Chief Executive Officer

Leap Therapeutics, Inc.

617-714-0360

[email protected]

Matthew DeYoung

Investor Relations

Argot Partners

212-600-1902

[email protected]

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Leap Therapeutics Inc. published this content on 18 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 January 2022 22:11:09 UTC.

© Publicnow 2022

share with twitter

share with LinkedIn

share with facebook

All news about LEAP THERAPEUTICS, INC.
05:12p LEAP THERAPEUTICS : to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus..

PU

05:07p LEAP THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

AQ

01/05 Leap Therapeutics to Present at H.C. Wainwright BioConnect 2022 Conference

PR

01/03 Leap Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

PR

2021 Certain Common Stock of Leap Therapeutics, Inc. are subject to a Lock-Up Agreement Endi..

CI

2021 Certain Pre-Funded Warrants of Leap Therapeutics, Inc. are subject to a Lock-Up Agreeme..

CI

2021 LEAP THERAPEUTICS, INC.(NASDAQGM : LPTX) added to NASDAQ Biotechnology Index

CI

2021 Leap Therapeutics to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Co..

PR

2021 Leap Therapeutics Reports Third Quarter 2021 Financial Results – Form 8-K

PU

2021 Earnings Flash (LPTX) LEAP THERAPEUTICS Posts Q3 Revenue $375,000

MT

Analyst Recommendations on LEAP THERAPEUTICS, INC.
2021 LEAP THERAPEUTICS : Mizuho Securities Starts Leap Therapeutics at Buy With $6 Price Target

MT

2021 LEAP THERAPEUTICS : Raymond James Lifts Leap Therapeutics’ Price Target to $4 from $3, Kee..

MT

2021 ANALYST RECOMMENDATIONS : American express, CrowdStrike, Five Below, J.M. Smucker, Lululem..

logo at

Financials (USD)

Sales 2021 1,42 M – –
Net income 2021 -41,1 M – –
Net Debt 2021 – – –
P/E ratio 2021 -5,77x
Yield 2021 –
Capitalization 251 M 251 M –
Capi. / Sales 2021 176x
Capi. / Sales 2022 139x
Nbr of Employees 30
Free-Float –
Chart LEAP THERAPEUTICS, INC.

Duration : Period :

3C CandleStick on

Leap Therapeutics, Inc. Technical Analysis Chart | MarketScreener

Technical analysis trends LEAP THERAPEUTICS, INC.

Short Term Mid-Term Long Term
Trends Neutral Neutral Bullish

Income Statement Evolution

Consensus

Sell

consensus flch

Buy

Mean consensus BUY
Number of Analysts 5
Last Close Price 2,84 $
Average target price 4,80 $
Spread / Average Target 69,0%

EPS Revisions

Managers and Directors

Doug E. Onsi President, CEO, CFO, Secretary & Treasurer
Chris K. Mirabelli Chairman
Cynthia Sirard Chief Medical Officer
Michael Haas Head-Research
Augustine J. Lawlor Chief Operating Officer

Sector and Competitors

1st jan. Capi. (M$)
us LEAP THERAPEUTICS, INC. -12.35% 251
us GILEAD SCIENCES, INC. -1.16% 90 027
us REGENERON PHARMACEUTICALS -2.58% 64 327
us VERTEX PHARMACEUTICALS 6.58% 59 510
cn WUXI APPTEC CO., LTD. -0.66% 52 665
us BIONTECH SE -23.97% 47 338

Read More Here

Related Posts

head-to-head-survey:-voyager-therapeutics-(nasdaq:vygr)-&-surface-oncology-(nasdaq:surf)

Head-To-Head Survey: Voyager Therapeutics (NASDAQ:VYGR) & Surface Oncology (NASDAQ:SURF)

by Duong
April 14, 2022
0

Posted by admin on Apr 14th, 2022 Voyager Therapeutics (NASDAQ:VYGR – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk...

energy-workshop-–-announcements-–-e-flux

Energy Workshop – Announcements – E-Flux

by Duong
April 13, 2022
0

The first edition of the Norman Foster Foundation’s Energy Workshop will take place from April 25–29, 2022 with the support of GS Energy. “With energy, we stand on the shoulders of giants with our heads in the clouds,” states the workshop’s Mentor, Luke Olsen. As he puts it, “we need to...

men’s-and-women’s-tennis-complete-successful-weekend-with-wins-over-columbia,-cornell-|-sports-|-the-harvard-crimson

Men’s And Women’s Tennis Complete Successful Weekend With Wins Over Columbia, Cornell | Sports | The Harvard Crimson

by NewsReporter
April 12, 2022
0

“One thing that our team has really come a long way in this semester is with our confidence and belief in ourselves,” said first-year Holly Fischer. “So I think that even though we were down, everyone who was playing was fighting so hard and really leaving everything out on the...

artist-pritika-chowdhry’s-‘anti-memorials’-illustrate-what-is-excluded-from-collective-memories-of-partition

Artist Pritika Chowdhry’s ‘anti-Memorials’ Illustrate What Is Excluded From Collective Memories Of Partition

by Duong
April 11, 2022
0

The Jallianwala Bagh Massacre is one of the most significant events in the history of the sub-continent. Many people, including women and children, lost their lives on April 13, 1919, the day of Baisakhi when General Reginald Edward Dy ordered soldiers to open fire on the gathering — camping in...

Massachusetts Digital News

© 2021 Massachusetts Digital News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Massachusetts Digital News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT